Nostrum Biodiscovery, a spin-off from IRB Barcelona and the BSC-CNS, focuses on computational simulation to design new drugs and biotech molecules for the market.
The Senén Vilaró Prize is given each year by the “Consejo Social” of the UB and the Bosch i Gimpera Foundation to the best innovative company.
On 16 September, the ”la Caixa” Foundation presented the 79 grants for national and international research and innovation projects of excellence—among these four projects from the Institute for Research in Biomedicine (IRB Barcelona).
Among the beneficiaries of funding from ”la Caixa”, IRB Barcelona researchers Eduard Batlle and Raúl Méndez obtained two grants from the call for research projects in biomedicine and health, Meritxel Teixidó received a grant from the CaixaImpulse Programme, and Enrique Marcos was awarded a postdoctoral fellowship.
Characterised by a central theme “Questions for the future”,...
Modesto Orozco’s lab (IRB Barcelona) has published a study on the reaction mechanism of DNAzymes in Nature Catalysis.
DNAzymes, which are catalysers formed by DNA, have applications in biomedicine and biotechnology. These research results will contribute to advances in the design and improvement of catalysers for therapeutic purposes.
Modesto Orozco’s laboratory (IRB Barcelona) has published a study on the source of asymmetry between nucleic acid hybrid (RNA and DNA) in CHEM (Cell Press).
The results are a promising step towards enhancing gene therapies, which are applicable to many diseases.
A study done by scientists at IRB Barcelona can simulate and predict the shape of a molecule in function of its environment.
These results mark a milestone for the computational design of molecules with specific shape and features for agrochemical, technological and pharmaceutical applications.
ABC has published an article on a study led by Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This work has unravelled the mechanism of action of the mAb806 antibody, a drug used to treat glioblastoma. Published in the journal PNAS, the study lays the foundation for the extension of this treatment to more types of tumours and to more specific therapies.
Link to ABC
The antibody mAb806 is used to treat glioblastoma, although its mechanism of action has been unknown until now.
The study, published in the journal PNAS, paves the way to extend treatment with mAb806 to more types of tumours and to the development of more personalised therapies.
The Uruguayan newpaper La Diaria has published an article about recent research done by the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This team has achieved the first stable simulations of DNA crystals, thus allowing the study of the role of each molecular component in the stability and conformation of said crystals. The article includes quotes by Pablo Dans, a postdoctoral researcher at the centre, about the study: "What we want is to see how 3D DNA folding occurs and understand how it correlates with the activity of a specific gene. This kind of work has a great plus in that you can see the DNA structure inside the nucleus, and you can manipulate it in three...
The breakthrough made by researchers at IRB Barcelona allows the study of the role of each molecular component in the stability and conformation of DNA crystals.
The new molecular simulation techniques are expected to reduce the time and cost of obtaining crystals in the laboratory.
Modesto Orozco’s lab has published a paper in Chemical Communications about a therapeutic tool to prevent treatment resistance in breast cancer.
The tool has been tested in tumour cells in vitro and will now need to be tested in animal models before moving on to the development of a valid treatment for patients.